Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 1.00 |
| ▸ | ITGAV | P06756 | 17/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 7/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 7/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 4/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31321064 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7168382 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL6657173 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL30894723 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7170698 | 0.91 | ITGB3 (0.83) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7168393 | 0.91 | ITGB3 (0.82) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7172016 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7170011 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7451419 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL7037993 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689787-B1 | POTENTIATING TUMOR RESPONSE | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| US-20040024044-A1 | Exemestane as chemopreventing agent | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-05 | — | — | US | claimed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | claimed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | claimed |
| EP-1549344-B1 | PHARMACEUTICAL COMPOSITIONS DIRECTED TO ERB-B1 RECEPTORS | MERCK PATENT GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2335733-B1 | Specific therapy using integrin ligands for treating cancer | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-1973569-B1 | SPECIFIC THERAPY USING INTEGRIN LIGANDS FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2013-05-22 | — | — | EP | disclosed |
| EP-2578225-A1 | Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer | Merck Patent GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-2101805-B1 | INTEGRIN LIGANDS FOR USE IN TREATING CANCER | MERCK PATENT GMBH (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-20120130146-A1 | CONTINUOUS ADMINISTRATION OF CILENGITIDE IN CANCER TREATMENTS | MERCK PATENT GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2445534-A2 | CONTINUOUS ADMINISTRATION OF CILENGITIDE IN CANCER TREATMENTS | Merck Patent GmbH (DE) | 2012-05-02 | — | — | EP | disclosed |
| EP-2441464-A1 | Specific therapy and medicament using integrin ligands for treating cancer | Merck Patent GmbH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20040052785-A1 | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | MERCK PATENT GMBH (DE) | 2004-03-18 | — | — | US | disclosed |
| US-20040024044-A1 | Exemestane as chemopreventing agent | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-05 | — | — | US | disclosed |
| EP-1385546-A1 | COMBINATION THERAPY USING ANTI-EGFR ANTIBODIES AND ANTI-HORMONAL AGENTS | MERCK PATENT GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1381384-A2 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFa | MERCK PATENT GmbH (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| WO-2002089842-A1 | COMBINATION THERAPY USING ANTI-EGFR ANTIBODIES AND ANTI-HORMONAL AGENTS | MERCK PATENT GMBH (DE) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002085405-A2 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a) | MERCK PATENT GMBH (DE) | 2002-10-31 | — | — | WO | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | ITGB3 153/4885ITGAV 168/4885ITGA2B 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.